A generic pharmaceutical company’s move to preserve litigation options in case an appellate court reversed its lower court win on one set of grounds was "particularly egregious," the Federal Circuit has ruled.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *